Celgene International Sàrl, a subsidiary of Celgene Corporation , today announced that results from three phase III studies evaluating the use of continuous REVLIMID® treatment in newly diagnosed multiple myeloma patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.